Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

OBJECTIVES: Abatacept is the only agent currently approved to treat rheumatoid arthritis (RA) that targets the co-stimulatory signal required for full T-cell activation. No studies have been conducted on its effect on the synovium, the primary site of pathology. The aim of this study was to determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Buch, M H, Boyle, D L, Rosengren, S, Saleem, B, Reece, R J, Rhodes, L A, Radjenovic, A, English, A, Tang, H, Vratsanos, G, O’Connor, P, Firestein, G S, Emery, P
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2009
Materias:
Basic and Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689522/
https://www.ncbi.nlm.nih.gov/pubmed/18772191
http://dx.doi.org/10.1136/ard.2008.091876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689522/
https://www.ncbi.nlm.nih.gov/pubmed/18772191
http://dx.doi.org/10.1136/ard.2008.091876

Ejemplares similares